title: The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma.
authors.affiliation: 1] INSERM, UMR892, Nantes, France [2] Université de Nantes, Nantes, France [3] CNRS, UMR 6299, Nantes, France [4] Service d'Hématologie Clinique, Unité d'Investigation Clinique, Centre Hospitalier Universitaire de Nantes, Nantes, France.
authors.forename: C
authors.initials: C
authors.lastname: Touzeau
authors.affiliation: 1] INSERM, UMR892, Nantes, France [2] Université de Nantes, Nantes, France [3] CNRS, UMR 6299, Nantes, France [4] CIC, INSERM, Nantes, France.
authors.forename: C
authors.initials: C
authors.lastname: Dousset
authors.affiliation: 1] INSERM, UMR892, Nantes, France [2] Université de Nantes, Nantes, France [3] CNRS, UMR 6299, Nantes, France [4] Service d'Hématologie Clinique, Unité d'Investigation Clinique, Centre Hospitalier Universitaire de Nantes, Nantes, France [5] CIC, INSERM, Nantes, France.
authors.forename: S
authors.initials: S
authors.lastname: Le Gouill
authors.affiliation: Department of Translational Oncology, Genentech, South San Francisco, CA, USA.
authors.forename: D
authors.initials: D
authors.lastname: Sampath
authors.affiliation: AbbVie Inc., North Chicago, IL, USA.
authors.forename: J D
authors.initials: JD
authors.lastname: Leverson
authors.affiliation: AbbVie Inc., North Chicago, IL, USA.
authors.forename: A J
authors.initials: AJ
authors.lastname: Souers
authors.affiliation: 1] INSERM, UMR892, Nantes, France [2] Université de Nantes, Nantes, France [3] CNRS, UMR 6299, Nantes, France.
authors.forename: S
authors.initials: S
authors.lastname: Maïga
authors.affiliation: Service d'Hématologie-biologie, Centre Hospitalier Universitaire de Nantes, Nantes, France.
authors.forename: M C
authors.initials: MC
authors.lastname: Béné
authors.affiliation: 1] INSERM, UMR892, Nantes, France [2] Université de Nantes, Nantes, France [3] Service d'Hématologie Clinique, Unité d'Investigation Clinique, Centre Hospitalier Universitaire de Nantes, Nantes, France [4] CIC, INSERM, Nantes, France.
authors.forename: P
authors.initials: P
authors.lastname: Moreau
authors.affiliation: 1] INSERM, UMR892, Nantes, France [2] Université de Nantes, Nantes, France [3] CNRS, UMR 6299, Nantes, France.
authors.forename: C
authors.initials: C
authors.lastname: Pellat-Deceunynck
authors.affiliation: 1] INSERM, UMR892, Nantes, France [2] Université de Nantes, Nantes, France [3] CNRS, UMR 6299, Nantes, France.
authors.forename: M
authors.initials: M
authors.lastname: Amiot
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000627:therapeutic use*; D002880:Chromosomes, Human, Pair 11; D002883:Chromosomes, Human, Pair 14; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000235:genetics*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000187:drug effects*; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D019086:Bridged Bicyclo Compounds, Heterocyclic; D019253:Proto-Oncogene Proteins c-bcl-2; D013449:Sulfonamides; C579720:venetoclax